US2005222016A1PendingUtilityA1

Nucleoside analogs in combination therapy of herpes simplex infections

52
Individually held — no corporate assignee on recordPriority: Jan 26, 1996Filed: Apr 14, 2005Published: Oct 6, 2005
Est. expiryJan 26, 2016(expired)· nominal 20-yr term from priority
Inventors:Malcolm Richard Boyd
A61P 31/12A61K 31/522A61P 31/22A61K 31/675A61K 38/13A61K 31/573A61P 31/00A61K 31/66A61K 31/57A61K 31/52
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as penciclorivir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.

Claims

exact text as granted — not AI-modified
1 - 6 . (canceled)  
   
   
       7 . A pharmaceutical composition comprising an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir, or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.  
   
   
       8 . A method of treatment or prophylaxis of herpes simplex virus infections in a human in need thereof, which method comprises administering to said human, an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir, or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.  
   
   
       9 . The composition according to  claim 7  wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.  
   
   
       10 . The composition according to  claim 9 , wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporin A, hydrocortisone, and dexamethasone.  
   
   
       11 . The method according to  claim 8 , wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.  
   
   
       12 . The method according to  claim 11 , wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporin A, hydrocortisone, and dexamethasone.  
   
   
       13 . A method of treatment or prophylaxis of a herpes simplex virus infection in a human in need thereof, which method comprises administering simultaneously to said human an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir, or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.  
   
   
       14 . The method according to  claim 13 , wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.  
   
   
       15 . The method according to  claim 14 , wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporin A, hydrocortisone, and dexamethasone.  
   
   
       16 . A method of treatment or prophylaxis of herpes simplex virus infection in a human in need thereof, which method comprises administering separately or sequentially to said human or animal an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir, or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.  
   
   
       17 . The method according to  claim 16 , wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.  
   
   
       18 . The method according to  claim 17 , wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporin A, hydrocortisone, and dexamethasone.  
   
   
       19 . A pharmaceutical composition according to  claim 7 , wherein the composition is adapted for parenteral administration.  
   
   
       20 . A pharmaceutical composition according to  claim 7 , wherein the Composition is adapted for oral administration.  
   
   
       21 . A method according to  claim 8 , wherein at least one of the nucleoside analogues or immunosuppressants is administered parenterally.  
   
   
       22 . A method according to  claim 8 , wherein at least one of the nucleoside analogues or immunosuppressants is administered orally.

Join the waitlist — get patent alerts

Track US2005222016A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.